GLAUKOS Corp

Glaukos Corporation (NASDAQ: GLAUKOS) operates as an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies for treating glaucoma, corneal disorders, and retinal disease. The company maintains its corporate headquarters and primary research and development operations in Aliso Viejo, California, with additional manufacturing and distribution facilities in San Clemente and Burlington, Massachusetts, and international subsidiaries across Australia, Brazil, Canada, Germany, Japan, and the United Kingdom. More information about the company is available at www.glaukos.com.

The company's commercial portfolio centers on five principal platforms addressing multiple therapeutic areas within ophthalmology. The iStent family of micro-scale surgical devices, including the iStent, iStent inject W, and iStent infinite, represents the company's flagship glaucoma treatment line, collectively accounting for the majority of revenue alongside related accessories. iDose TR, a first-of-its-kind intracameral procedural pharmaceutical implant approved by the FDA in December 2023, delivers glaucoma medication continuously inside the eye for extended periods. The iLink platform comprises bio-activated pharmaceutical therapies for corneal disorders, including keratoconus treatment through corneal collagen cross-linking technology. The company also develops the iLution transdermal pharmaceutical platform for anterior segment disorders and the Retinal XR platform targeting posterior segment diseases including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

For the fiscal year ended December 31, 2025, glaucoma-related products including the iStent family, iDose TR, and accessories represented approximately eighty-three percent of net sales, while iLink therapies and associated products accounted for approximately seventeen percent. The company operates through a direct sales organization in the United States, capturing seventy-four percent of revenue, while international markets represent twenty-six percent. The company distributes products through its own facilities and third-party logistics providers, maintaining manufacturing operations across multiple locations to support its growing product portfolio and pipeline development initiatives.